Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Innovent Biologics Inc (1801)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
39.05 +0.90    +2.36%
24/04 - Delayed Data. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  KYG4818G1010 
  • Volume: 4,843,436
  • Bid/Ask: 39.00 / 39.10
  • Day's Range: 37.95 - 39.70
Innovent Biologics 39.05 +0.90 +2.36%

1801 Balance Sheet

 
Featured here, the Balance Sheet for Innovent Biologics Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Current Assets 13427.98 13427.98 11385.31 11385.31
Cash and Short Term Investments 10969.63 10969.63 8526.49 8526.49
Cash - - - -
Cash & Equivalents 10052.1 10052.1 7655.66 7655.66
Short Term Investments 917.53 917.53 - -
Total Receivables, Net 1005.89 1005.89 1019.31 1019.31
Accounts Receivables - Trade, Net 1005.89 1005.89 1015.5 1015.5
Total Inventory 968.09 968.09 1300.03 1300.03
Prepaid Expenses - - - -
Other Current Assets, Total 484.38 484.38 539.48 539.48
Total Assets 20627.36 20627.36 17897.04 17897.04
Property/Plant/Equipment, Total - Net 4656.38 4656.38 4187.13 4187.13
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - -
Intangibles, Net 1270.27 1270.27 1190.44 1190.44
Long Term Investments 794.09 794.09 636.65 636.65
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 478.64 478.64 497.5 497.5
Other Assets, Total 1364.11 1364.11 1694.84 1694.84
Total Current Liabilities 4476.82 4476.82 2872.46 2872.46
Accounts Payable 372.55 372.55 216.41 216.41
Payable/Accrued - - - -
Accrued Expenses - - 1529.32 1529.32
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 1220.33 1220.33 477.12 477.12
Other Current liabilities, Total 2883.94 2883.94 649.62 649.62
Total Liabilities 8099.78 8099.78 7113.82 7113.82
Total Long Term Debt 2400.2 2400.2 2975.18 2975.18
Long Term Debt 2326.78 2326.78 2888.47 2888.47
Capital Lease Obligations 73.42 73.42 86.72 86.72
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 1222.76 1222.76 -2072.39 1266.17
Total Equity 12527.58 12527.58 10783.22 10783.22
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.112 0.112 0.106 0.106
Additional Paid-In Capital - - 24900.16 24900.16
Retained Earnings (Accumulated Deficit) - - -14878.8 -14878.8
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 12527.47 12527.47 761.76 761.76
Total Liabilities & Shareholders' Equity 20627.36 20627.36 17897.04 17897.04
Total Common Shares Outstanding 1583.95 1583.95 1540.72 1540.72
Total Preferred Shares Outstanding - - - -
* In Millions of CNY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

1801 Comments

Write your thoughts about Innovent Biologics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
JAME Megueni
VRAQ Feb 13, 2022 9:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
*M Stanley Trims INNOVENT BIO TP to $65, Rated Overweight
Reply
1 0
Report
JAME Megueni
VRAQ Jan 24, 2022 9:00PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
UBS Axes INNOVENT BIO TP to $65, Rated Buy
Reply
1 0
Report
JAME Megueni
VRAQ Jan 20, 2022 8:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
*HSBC Global Research Cuts INNOVENT BIO TP to $85, Rated Buy
Reply
1 0
Report
JAME Megueni
VRAQ Aug 29, 2021 11:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
C Suisse Cuts INNOVENT BIO TP to $90; Rated Outperform
Reply
1 0
Report
JAME Megueni
VRAQ Aug 23, 2021 12:09AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
M Stanley Assumes INNOVENT BIO Shr Hike in 15 Days; Rated Overweight
Reply
1 0
Report
JAME Megueni
VRAQ Apr 28, 2021 4:04AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Daiwa Sees INNOVENT BIO as Sector Top-pick; 1Q Sintilimab Sales In Line
Reply
1 0
Report
JAME Megueni
VRAQ Mar 07, 2021 9:42PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
UBS Lifts INNOVENT BIO TP to $132.9, Downgrades INNOCARE-B (09969.HK) to ***Neutral*** (Correct)
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email